Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRNX - US22663K1079 - Common Stock

53.24 USD
-0.1 (-0.19%)
Last: 1/8/2026, 8:00:01 PM
54.0645 USD
+0.82 (+1.55%)
After Hours: 1/8/2026, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRNX. CRNX was compared to 191 industry peers in the Pharmaceuticals industry. While CRNX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRNX has reported negative net income.
In the past year CRNX has reported a negative cash flow from operations.
In the past 5 years CRNX always reported negative net income.
In the past 5 years CRNX always reported negative operating cash flow.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

CRNX has a Return On Assets (-35.38%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -39.46%, CRNX is in line with its industry, outperforming 56.54% of the companies in the same industry.
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRNX has more shares outstanding
Compared to 5 years ago, CRNX has more shares outstanding
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 22.74 indicates that CRNX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 22.74, CRNX belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.74
ROIC/WACCN/A
WACC9.46%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 15.12 indicates that CRNX has no problem at all paying its short term obligations.
The Current ratio of CRNX (15.12) is better than 84.82% of its industry peers.
CRNX has a Quick Ratio of 15.12. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
CRNX's Quick ratio of 15.12 is amongst the best of the industry. CRNX outperforms 85.34% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CRNX have decreased strongly by -21.45% in the last year.
CRNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.74%.
CRNX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.68% yearly.
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.31% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 273.06% on average over the next years. This is a very strong growth
EPS Next Y-37.76%
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%
EPS Next 5Y22.31%
Revenue Next Year224.94%
Revenue Next 2Y482.25%
Revenue Next 3Y384.21%
Revenue Next 5Y273.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%

More info and screens

0

5. Dividend

5.1 Amount

CRNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (1/8/2026, 8:00:01 PM)

After market: 54.0645 +0.82 (+1.55%)

53.24

-0.1 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners115.45%
Inst Owner Change0%
Ins Owners1.71%
Ins Owner Change3.94%
Market Cap5.05B
Revenue(TTM)1.53M
Net Income(TTM)-423.10M
Analysts83.64
Price Target81.75 (53.55%)
Short Float %15.48%
Short Ratio11.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.77%
Min EPS beat(2)-9.79%
Max EPS beat(2)-7.76%
EPS beat(4)1
Avg EPS beat(4)-5.74%
Min EPS beat(4)-9.79%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6.07%
EPS beat(12)1
Avg EPS beat(12)-6.18%
EPS beat(16)2
Avg EPS beat(16)-6.92%
Revenue beat(2)1
Avg Revenue beat(2)310.54%
Min Revenue beat(2)-61.44%
Max Revenue beat(2)682.52%
Revenue beat(4)2
Avg Revenue beat(4)202.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)682.52%
Revenue beat(8)3
Avg Revenue beat(8)91.58%
Revenue beat(12)7
Avg Revenue beat(12)151.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.98%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-5.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-7.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3291.17
P/FCF N/A
P/OCF N/A
P/B 4.71
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-4.53
EYN/A
EPS(NY)-5.4
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.69
OCFYN/A
SpS0.02
BVpS11.3
TBVpS11.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.91%
Cap/Sales 412.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 22.74
F-Score3
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
EPS Next Y-37.76%
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%
EPS Next 5Y22.31%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A
Revenue Next Year224.94%
Revenue Next 2Y482.25%
Revenue Next 3Y384.21%
Revenue Next 5Y273.06%
EBIT growth 1Y-55.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.55%
EBIT Next 3Y-3.6%
EBIT Next 5YN/A
FCF growth 1Y-113.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.54%
OCF growth 3YN/A
OCF growth 5YN/A

CRINETICS PHARMACEUTICALS IN / CRNX FAQ

What is the ChartMill fundamental rating of CRINETICS PHARMACEUTICALS IN (CRNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRNX.


Can you provide the valuation status for CRINETICS PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 0 / 10 to CRINETICS PHARMACEUTICALS IN (CRNX). This can be considered as Overvalued.


What is the profitability of CRNX stock?

CRINETICS PHARMACEUTICALS IN (CRNX) has a profitability rating of 1 / 10.